Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Fernando P. Polack, Stephen J. Thomas, Nicholas Kitchin, et al.
New England Journal of Medicine (2020) Vol. 383, Iss. 27, pp. 2603-2615
Open Access | Times Cited: 13697

Showing 1-25 of 13697 citing articles:

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Lindsey R. Baden, Hana M. El Sahly, Brandon Essink, et al.
New England Journal of Medicine (2020) Vol. 384, Iss. 5, pp. 403-416
Open Access | Times Cited: 6978
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
David S. Khoury, Deborah Cromer, Arnold Reynaldi, et al.
Nature Medicine (2021) Vol. 27, Iss. 7, pp. 1205-1211
Open Access | Times Cited: 3729
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
Jamie Lopez Bernal, Nick Andrews, Charlotte Gower, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 7, pp. 585-594
Open Access | Times Cited: 2900
Features, Evaluation and Treatment Coronavirus (COVID-19)
Marco Cascella, Michael Rajnik, Arturo Cuomo, et al.
StatPearls (2020)
Closed Access | Times Cited: 2796
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
Noa Dagan, Noam Barda, Eldad Kepten, et al.
New England Journal of Medicine (2021) Vol. 384, Iss. 15, pp. 1412-1423
Open Access | Times Cited: 2543
Mechanisms of SARS-CoV-2 entry into cells
Cody B. Jackson, Michael Farzan, Bing Chen, et al.
Nature Reviews Molecular Cell Biology (2021) Vol. 23, Iss. 1, pp. 3-20
Open Access | Times Cited: 2410
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
Pengfei Wang, Manoj S. Nair, Lihong Liu, et al.
Nature (2021) Vol. 593, Iss. 7857, pp. 130-135
Open Access | Times Cited: 2239
Lipid nanoparticles for mRNA delivery
Xucheng Hou, Tal Zaks, Róbert Langer, et al.
Nature Reviews Materials (2021) Vol. 6, Iss. 12, pp. 1078-1094
Open Access | Times Cited: 2117
Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant
Nick Andrews, Julia Stowe, Freja Kirsebom, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 16, pp. 1532-1546
Open Access | Times Cited: 2091
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
Denis Y. Logunov, Inna V. Dolzhikova, Dmitry V. Shcheblyakov, et al.
The Lancet (2021) Vol. 397, Iss. 10275, pp. 671-681
Open Access | Times Cited: 1715
Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data
Eric J. Haas, Frederick J. Angulo, John M. McLaughlin, et al.
The Lancet (2021) Vol. 397, Iss. 10287, pp. 1819-1829
Open Access | Times Cited: 1630
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
Zijun Wang, Fabian Schmidt, Yiska Weisblum, et al.
Nature (2021) Vol. 592, Iss. 7855, pp. 616-622
Open Access | Times Cited: 1438
Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity
Wilfredo F. García-Beltrán, Evan C. Lam, Kerri St. Denis, et al.
Cell (2021) Vol. 184, Iss. 9, pp. 2372-2383.e9
Open Access | Times Cited: 1429
Covid-19 Breakthrough Infections in Vaccinated Health Care Workers
Moriah Bergwerk, Tal Gonen, Yaniv Lustig, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 16, pp. 1474-1484
Open Access | Times Cited: 1364
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
Shabir A. Madhi, Vicky L. Baillie, Clare Cutland, et al.
New England Journal of Medicine (2021) Vol. 384, Iss. 20, pp. 1885-1898
Open Access | Times Cited: 1270
Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study
Jamie Lopez Bernal, Nick Andrews, Charlotte Gower, et al.
BMJ (2021), pp. n1088-n1088
Open Access | Times Cited: 1202
Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
Sara Y. Tartof, Jeff Slezak, Heidi Fischer, et al.
The Lancet (2021) Vol. 398, Iss. 10309, pp. 1407-1416
Open Access | Times Cited: 1166
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
Merryn Voysey, Sue Ann Costa Clemens, Shabir A. Madhi, et al.
The Lancet (2021) Vol. 397, Iss. 10277, pp. 881-891
Open Access | Times Cited: 1143
A guide to vaccinology: from basic principles to new developments
Andrew J. Pollard, Else M. Bijker
Nature reviews. Immunology (2020) Vol. 21, Iss. 2, pp. 83-100
Open Access | Times Cited: 1140
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
Shuo Feng, Daniel J. Phillips, Thomas White, et al.
Nature Medicine (2021) Vol. 27, Iss. 11, pp. 2032-2040
Open Access | Times Cited: 1104
Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera
Daming Zhou, Wanwisa Dejnirattisai, Piyada Supasa, et al.
Cell (2021) Vol. 184, Iss. 9, pp. 2348-2361.e6
Open Access | Times Cited: 1099
Therapeutic peptides: current applications and future directions
Lei Wang, Nanxi Wang, Wenping Zhang, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 1083
Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months
E G Levin, Yaniv Lustig, Carmit Cohen, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 24
Open Access | Times Cited: 1083
Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape
John S. Tregoning, Katie E. Flight, Sophie L. Higham, et al.
Nature reviews. Immunology (2021) Vol. 21, Iss. 10, pp. 626-636
Open Access | Times Cited: 1031
mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant
Wilfredo F. García-Beltrán, Kerri St. Denis, Angelique Hœlzemer, et al.
Cell (2022) Vol. 185, Iss. 3, pp. 457-466.e4
Open Access | Times Cited: 1020
Page 1 - Next Page

Scroll to top